| Opdivo | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Active not recruiting | 76 | Feb 5, 2027 |
| BMS-986435 | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Active not recruiting | 227 | Dec 14, 2026 |
| phenoxymethyl penicillin | GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial | Phase 2 | Completed | 1,004 | Oct 31, 2026 |
| Revlimid | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | Phase 2 | Completed | 36 | Aug 28, 2026 |
| Sprycel | Improving Physical Ability and Cellular Senescence Elimination in HIV | Phase 2 | Completed | 82 | Aug 26, 2026 |
| Opdivo | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | Phase 2 | Terminated | 5 | Aug 13, 2026 |
| Adagrasib | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Phase 2 | Active not recruiting | 200 | Jul 30, 2026 |
| BMS-986165 | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis | Phase 3 | Completed | 1,466 | Jul 21, 2026 |
| Mezigdomide | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | Phase 3 | Active not recruiting | 606 | Jul 18, 2026 |
| Opdivo | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | Phase 3 | Completed | 732 | Jul 9, 2026 |
| HBI-8000 in combination with nivolumab | Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma | Phase 3 | Active not recruiting | 450 | Jul 2026 |
| Opdivo | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | Phase 2 | Completed | 44 | Jun 19, 2026 |
| Opdivo | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | Phase 2 | Completed | 18 | Jun 17, 2026 |
| Nulojix | Abatacept Conversion in Kidney Transplantation | Phase 2 | Completed | 87 | Jun 10, 2026 |
| Opdivo | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | Phase 2 | Completed | 10 | Jun 1, 2026 |
| Inrebic | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | Phase 2 | Active not recruiting | 216 | May 31, 2026 |
| Opdivo | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Phase 2 | Active not recruiting | 150 | May 30, 2026 |
| Opdivo | PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma | Phase 2 | Completed | 37 | May 1, 2026 |
| Onureg | Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT | Phase 3 | Completed | 326 | Apr 29, 2026 |
| Sprycel | Senolytics to Improve Osteoporosis Therapy | Phase 2 | Completed | 120 | Apr 24, 2026 |
| Ipilimumab/ Nivolumab | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer | Phase 2 | Completed | 66 | Apr 23, 2026 |
| Abecma | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | Phase 3 | Completed | 386 | Apr 13, 2026 |
| Nulojix | Daratumumab and Belatacept for Desensitization | Phase 2 | Completed | 19 | Apr 2, 2026 |
| Xanomeline and Trospium Chloride Capsules | An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | Phase 3 | Completed | 290 | Mar 25, 2026 |
| Opdivo | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | Phase 2 | Completed · results | 33 | Mar 12, 2026 |
| Opdivo | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | Phase 2 | Terminated | 15 | Mar 11, 2026 |
| Ipilimumab | Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer | Phase 2 | Terminated | 1 | Mar 9, 2026 |
| N-acetyl cysteine | Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial | Phase 3 | Completed | 202 | Mar 2, 2026 |
| Sprycel | Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | 30 | Feb 26, 2026 |
| Empliciti | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | Phase 2 | Completed | 67 | Feb 23, 2026 |
| Opdivo | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer | Phase 3 | Completed | 855 | Feb 16, 2026 |
| Opdivo | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | Phase 2 | Terminated | 15 | Feb 1, 2026 |
| Revlimid | Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | Phase 3 | Completed | 514 | Jan 30, 2026 |
| JPB898 (Induction and Maintenance) | Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® | Phase 3 | Terminated | 52 | Jan 23, 2026 |
| Opdivo | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | Phase 3 | Completed | 343 | Jan 20, 2026 |
| Camzyos | A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM | Phase 3 | Completed | 314 | Jan 16, 2026 |
| Abecma | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | Phase 2 | Completed | 312 | Jan 15, 2026 |
| probenecid | The Re-Prosper HF Study | Phase 3 | Completed · results | 125 | Dec 31, 2025 |
| Opdivo | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | Phase 2 | Completed · results | 26 | Dec 15, 2025 |
| Opdivo | Study of DF1001 in Patients With Advanced Solid Tumors | Phase 2 | Completed | 270 | Dec 5, 2025 |